These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32100879)

  • 21. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors.
    Jiao J; Watt GP; Stevenson HL; Calderone TL; Fisher-Hoch SP; Ye Y; Wu X; Vierling JM; Beretta L
    Hepatol Commun; 2018 Jun; 2(6):718-731. PubMed ID: 29881823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection.
    Chen YL; Jeng YM; Chang CN; Lee HJ; Hsu HC; Lai PL; Yuan RH
    Int J Surg; 2014; 12(7):659-65. PubMed ID: 24866078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease.
    Akuta N; Kawamura Y; Suzuki F; Kobayashi M; Arase Y; Saitoh S; Muraishi N; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Ikeda K; Kumada H
    Hepatol Int; 2022 Apr; 16(2):412-422. PubMed ID: 35306637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic analysis with the hierarchical cluster analysis strategy on the complex interaction of TERT and CTNNB1 somatic mutations in Vietnamese hepatocellular carcinoma patients.
    Thu Nguyen T; Van Tran K; Cam Ho T; Xuan Nguyen H; Trong Nguyen T
    Gene; 2024 Nov; 927():148646. PubMed ID: 38851365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.
    El-Mazny A; Sayed M; Sharaf S
    Arab J Gastroenterol; 2014 Jun; 15(2):68-71. PubMed ID: 25097049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
    Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
    Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA.
    Hlady RA; Zhao X; Pan X; Yang JD; Ahmed F; Antwi SO; Giama NH; Patel T; Roberts LR; Liu C; Robertson KD
    Theranostics; 2019; 9(24):7239-7250. PubMed ID: 31695765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of TERT promoter mutations in primary tumors of the liver.
    Quaas A; Oldopp T; Tharun L; Klingenfeld C; Krech T; Sauter G; Grob TJ
    Virchows Arch; 2014 Dec; 465(6):673-7. PubMed ID: 25267585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
    Ko E; Seo HW; Jung ES; Kim BH; Jung G
    Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
    Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
    Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
    Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
    Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
    Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines.
    Hirata M; Fujita K; Fujihara S; Mizuo T; Nakabayashi R; Kono T; Namima D; Fujita N; Yamana H; Kamada H; Tani J; Kobara H; Tsutsui K; Matsuda Y; Ono M; Masaki T
    In Vivo; 2022; 36(1):94-102. PubMed ID: 34972704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR.
    Liu J; Zhao Z; Sun M; Chen K; Yuan W; Jiang G
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):90-3. PubMed ID: 26741813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.
    Miura N; Maeda Y; Kanbe T; Yazama H; Takeda Y; Sato R; Tsukamoto T; Sato E; Marumoto A; Harada T; Sano A; Kishimoto Y; Hirooka Y; Murawaki Y; Hasegawa J; Shiota G
    Clin Cancer Res; 2005 May; 11(9):3205-9. PubMed ID: 15867214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
    Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
    Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
    Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.
    Zheng X; Zhuge J; Bezerra SM; Faraj SF; Munari E; Fallon JT; Yang XJ; Argani P; Netto GJ; Zhong M
    J Hematol Oncol; 2014 Jul; 7():47. PubMed ID: 25042800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.